Abstract
Background Evidence based findings on long-term health-related consequences of a SARS-CoV-2 infection remain scarce. Data from wearable devices, well suited for continuous measurement of heart rate and physical activity, offers a unique opportunity to assess the impact of such infections on an individual’s health. Here we aim to characterize comprehensively how persistent self-reported symptoms during both acute and post-acute infection correlate to changes in resting heart rate (RHR) and physical activity, as measured by consumer-grade wearable sensors.
Methods Using a wearable-derived dataset of behavior and physiology (n = 20,815), we identified 137 individuals who are characterized by persistent fatigue and shortness of breath after a reported positive SARS-CoV-2 test. We compared this cohort with COVID-19 positive without persistent symptoms and negative controls. The comparison is based on measurements of RHR and physical activity as well as self-reported health-related Quality of Life (QoL) through WHO-5 and EQ-5D before, during, and after the infection.
Findings We identified a unique phenotype of persistent COVID-19 symptoms and associated wearable data characteristics and compared this phenotype to COVID-19 positive and negative controls. Individuals who reported persistent symptoms (coexisting shortness of breath and fatigue) showed higher RHRs (mean difference of 2 · 37/1 · 49 bpm), and lower daily step count (on average 3,030/2,909 steps less) compared to positive/negative controls, even at least three weeks prior to a SARS-CoV-2 infection. During the acute phase (0-4 weeks after a positive COVID-19 test), individuals with persistent shortness of breath and fatigue exhibited a decrease in mean RHR, 1 · 86 times that of individuals in the positive control cohort. Similarly, the persistent symptom phenotype took an average of seven days longer to return to normal compared to positive controls. Additionally we found that self-reported persistent COVID-19 symptoms are linked to a substantial reduction in mean QoL, even before infection.
Interpretation The analysis of individual wearable time-series suggests that the persistent symptom phenotype, characterized by shortness of breath and fatigue, may have been more exposed to pre-existing health conditions and/or exhibited lower levels of fitness prior to a SARS-CoV-2 infection. Our approach demonstrates the enormous potential in tracking the dynamics of physiological and physical activity under natural conditions in the context of infectious and chronic diseases.
Funding This study was funded in part by funds from the overall funding program of the City of Vienna MA7. Funding was also received from the Federal Ministry of Health of Germany (Grants “Corona-Datenspende”, CD21, DS22 and DS23).
Research in Context Evidence before this study: Previous research on persistent symptoms of the post-COVID-19 condition on heart rate and physical activity (measured in step count) often lacks a valid control group and/or information on the health status of individuals prior to the SARS-CoV-2 infection. The majority of studies have been conducted in clinical settings with a potential selection bias and do not account for post-COVID-19 conditions in the general population or its imprint on everyday life. Furthermore, knowledge on how lingering symptoms affect objectively measurable vital signals (such as heart rate and step count) in different phases of acute and post-acute infection regulation, is useful for enabling timely and targeted treatment interventions in clinical monitoring.
Added value of this study: By incorporating detailed data obtained from wearables prior to, during, and after infection, including symptoms, overall wellbeing, and pre-existing health conditions, we could effectively identify and thoroughly characterize individuals with persistent COVID-19 symptoms. This unique advantage of our approach enhances the interpretation of phases in post-acute infection regulation. It further facilitates a comprehensive analysis of both, perceived and physiological health status, providing a multifaceted view of post-COVID-19 condition. Additionally, the characterization of patient demographics, comorbidities, and Quality of Life (QoL) enriches our understanding of the population at risk for developing persistent symptoms.
Implications of the entire available evidence: We found that individuals experiencing persistent shortness of breath and fatigue, previously identified as core symptoms of post-COVID-19 condition, exhibit on average elevated resting heart rate (RHR), lower daily activity levels, lower QoL, and a higher count of pre-existing conditions already prior to an infection with SARS-CoV-2 compared to two control cohorts. In addition, the average decrease in RHR (bradycardia) during the acute phase of the infection was more pronounced and prolonged in those with persistent symptoms compared to the controls. These findings have helped to identify individuals at risk of developing persistent symptoms following SARS-CoV-2 infection and potentially assist tailoring diagnosis and treatment at an individual level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part with funds from the funding program of the City of Vienna MA7 with no role of the study sponsor in study design, collection, analysis, interpretation of the data, writing of the report and decision to submit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participation in the study was voluntary and self-recruited. All individuals participating in the Corona Data Donation Project provided informed consent electronically via the app. Consent was provided separately for submitting vital data and participating in the in-app surveys. Participation is only possible for German residents age 16 and older and data is only stored pseudonymously, using a randomly generated unique user ID. Participant age is rounded to 5 years. The study is subject to strict compliance with the data protection provisions set out in the EU General Data Protection Regulation (GDPR) and the Federal Data Protection Act (BDSG). A comprehensive privacy impact assessment was conducted through an external law-firm specialized in e-Health and research projects. The study was reviewed and approved by the Data Privacy Officer at the Robert Koch Institute (internal operation number 2021-009) in agreement with the Federal Commissioner for Data Protection and Freedom of Information (BfDI), Germany's highest independent supreme federal authority for data protection and freedom of information. Ethical approval for this study was obtained from the ethics board at the University of Erfurt (approval number 20220414).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Lead authors of the manuscript.
